According to The Indian Family Offices Report 2026 by 1Lattice, an AI and technology-enabled market intelligence and decision support platform, India has more than 300 family offices managing over $30 billion in assets.
The report noted that family offices are expanding their focus beyond wealth preservation towards private markets, alternative assets and sector-specific opportunities.
Healthcare is among the sectors drawing attention as investors look beyond traditional pharmaceutical companies and explore opportunities across the wider healthcare ecosystem.
A Ken Research, a global market intelligence and strategy consulting firm headquartered in Gurugram, India, estimate pegs India’s healthcare market at around ₹64.2 lakh crore in FY26, with investment opportunities emerging across hospitals, diagnostics, medical technology, pharmaceutical manufacturing and wellness businesses.
Industry experts said healthcare is gaining investor interest due to long-term trends such as ageing populations, rising chronic diseases, increasing healthcare access and technology-led changes in healthcare delivery.
Jami Balaji Rao, Founder of Dubai-based Niner Pharmaceuticals, a pharmaceutical and MedTech company, said healthcare combines relatively stable demand with long-term drivers such as ageing populations, rising chronic diseases and expanding healthcare access.
“For family offices focused on preserving capital across generations, healthcare offers a combination of resilience and long-term growth. The opportunity today extends beyond listed pharma to the broader healthcare value chain,” Rao said.
Cross-border structuring gaining attention
Rao said many founders are building businesses across India, the Gulf and other global markets, making cross-border structuring an important consideration for expansion.
He added that healthcare businesses require greater attention to regulatory compliance and governance because of the sector’s operating environment.
According to Rao, some family offices are also evaluating opportunities across manufacturing, distribution and healthcare supply chains instead of limiting themselves to financial investments.
“As healthcare supply chains become more global and regulated, trust is becoming the defining currency of pharmaceutical partnerships, with quality, compliance and consistency increasingly outweighing price alone when institutional buyers choose long-term partners,” Rao said.
Longevity, AI diagnostics among areas to watch
Looking ahead, Rao identified longevity therapeutics, AI-driven diagnostics, preventive healthcare and pharmaceutical manufacturing as areas that could present long-term opportunities.
He also pointed to resilient pharmaceutical supply chains as a theme to watch as governments seek to diversify sourcing of medicines and reduce supply disruptions.
Technology-led businesses also on investors’ radar
Saurabh Luthra, Founder of Eazzy, an Indian home services and appliance lifecycle management startup, said family offices are also evaluating technology-driven businesses that address long-term consumer needs.
“Healthcare, longevity and wellness are recession-resilient sectors where digital innovation is improving accessibility, efficiency and customer experience,” Luthra said.
He added that investors are looking for businesses with scalable technology platforms, sound governance and the potential to expand across markets. According to him, cross-border structuring is also becoming more relevant for founders seeking access to capital and new geographies.
Industry observers believe family office interest in healthcare is likely to remain strong as demographic shifts, preventive healthcare, digital innovation and supply-chain resilience continue to reshape global healthcare markets.
